Literature DB >> 21615608

Inactivation of Merlin in malignant mesothelioma cells and the Hippo signaling cascade dysregulation.

Yoshitaka Sekido1.   

Abstract

Malignant mesothelioma (MM) is an aggressive tumor arising primarily from pleural or peritoneal cavities, which is caused by asbestos exposure after long latency. One of the most frequently mutated genes detected in MM cells is the neurofibromatosis type 2 (NF2) tumor suppressor gene which is located at chromosome 22q12. The NF2 gene encodes Merlin, an ERM (Ezrin/Radixin/Moesin) protein. The underphosphorylated form of Merlin is active and acts as a tumor suppressor by regulating several distinct cellular signaling pathways. One of the downstream pathways regulated by Merlin is the Hippo signaling pathway, which is conserved from Drosophila to mammalian cells and plays important roles in organ size control and cancer development. Recent studies have identified alterations of the components in the Hippo signaling cascade in MM cells, including overexpression of Yes-associated protein (YAP) and inactivation of large tumor suppressor homolog 2 (LATS2). Dysregulation of the Merlin-Hippo signaling cascade is one of the frequent and key events of MM cell development and/or progression. Thus, a strategy to normalize this signaling cascade may be the rationale for developing a new target therapy against MM.
© 2011 The Author. Pathology International © 2011 Japanese Society of Pathology and Blackwell Publishing Asia Pty Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21615608     DOI: 10.1111/j.1440-1827.2011.02666.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  32 in total

Review 1.  Targeting the Hippo pathway in cancer, fibrosis, wound healing and regenerative medicine.

Authors:  Anwesha Dey; Xaralabos Varelas; Kun-Liang Guan
Journal:  Nat Rev Drug Discov       Date:  2020-06-17       Impact factor: 84.694

2.  Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma.

Authors:  Yoshiaki Kinoshita; Makoto Hamasaki; Masayo Yoshimura; Shinji Matsumoto; Akinori Iwasaki; Kazuki Nabeshima
Journal:  Mod Pathol       Date:  2019-06-23       Impact factor: 7.842

3.  Important recent insights into the genetics and biology of malignant pleural mesothelioma.

Authors:  Robert McMillan; Marjorie Zauderer; Matthew Bott; Marc Ladanyi
Journal:  Ann Cardiothorac Surg       Date:  2012-11

Review 4.  Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.

Authors:  Min Hwan Kim; Joon Kim
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

5.  New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Authors:  Marc Ladanyi; Marjorie G Zauderer; Lee M Krug; Tatsuo Ito; Robert McMillan; Matthew Bott; Filippo Giancotti
Journal:  Clin Cancer Res       Date:  2012-07-23       Impact factor: 12.531

6.  Integrated high-resolution array CGH and SKY analysis of homozygous deletions and other genomic alterations present in malignant mesothelioma cell lines.

Authors:  Geula Klorin; Ester Rozenblum; Oleg Glebov; Robert L Walker; Yoonsoo Park; Paul S Meltzer; Ilan R Kirsch; Frederic J Kaye; Anna V Roschke
Journal:  Cancer Genet       Date:  2013-07-05

Review 7.  Iron overload as a major targetable pathogenesis of asbestos-induced mesothelial carcinogenesis.

Authors:  Shinya Toyokuni
Journal:  Redox Rep       Date:  2013-11-20       Impact factor: 4.412

8.  MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma.

Authors:  Michaela B Kirschner; Yuen Yee Cheng; Nicola J Armstrong; Ruby C Y Lin; Steven C Kao; Anthony Linton; Sonja Klebe; Brian C McCaughan; Nico van Zandwijk; Glen Reid
Journal:  Mol Oncol       Date:  2014-12-02       Impact factor: 6.603

Review 9.  The Hippo Signaling Pathway in Development and Disease.

Authors:  Yonggang Zheng; Duojia Pan
Journal:  Dev Cell       Date:  2019-08-05       Impact factor: 12.270

Review 10.  Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer.

Authors:  Fa-Xing Yu; Bin Zhao; Kun-Liang Guan
Journal:  Cell       Date:  2015-11-05       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.